Use of sirolimus in the treatment of lymphangioleiomyomatosis: favorable responses in patients with different extrapulmonary manifestations

Use of sirolimus in the treatment of lymphangioleiomyomatosis: favorable responses in patients with different extrapulmonary manifestations

OBJECTIVE: Lymphangioleiomyomatosis (LAM) is a rare disease that is currently considered a low-grade neoplasm with metastatic potential and variable progression. Mammalian target of rapamycin (mTOR) inhibitors, such as sirolimus and everolimus, have recently become a treatment option for LAM patient...

Full description

Bibliographic Details
Main Authors: Carolina Salim Gonçalves Freitas, Bruno Guedes Baldi, Mariana Sponholz Araújo, Glaucia Itamaro Heiden, Ronaldo Adib Kairalla, Carlos Roberto Ribeiro Carvalho
Format: Article
Language:English
Published: Sociedade Brasileira de Pneumologia e Tisiologia 2015-06-01
Series:Jornal Brasileiro de Pneumologia
Subjects:
Neoplasias
Linfangioleiomiomatose
Serina-treonina quinases TOR
Sirolimo
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1806-37132015000300275&lng=en&tlng=en

Internet

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1806-37132015000300275&lng=en&tlng=en

Similar Items